Natera (HAM:45E) Accounts Payable: €65 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:45E Natera Inc HAM:45E
59 GF Score
Price €274.40
GF Value €185.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Natera Accounts Payable?

Natera HAM:45E +2.62% 59 Accounts Payable is €65 Mil as of Jun. 2026. GuruFocus rates HAM:45E with a GF Score™ of 59/100 and a GF Value™ of €185.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Natera's Accounts Payable for the quarter that ended in Jun. 2026 was €65 Mil.

Natera's quarterly Accounts Payable increased from Dec. 2025 (€28 Mil) to Mar. 2026 (€54 Mil) and increased from Mar. 2026 (€54 Mil) to Jun. 2026 (€65 Mil).

Natera's annual Accounts Payable increased from Dec. 2023 (€14 Mil) to Dec. 2024 (€33 Mil) but then declined from Dec. 2024 (€33 Mil) to Dec. 2025 (€28 Mil).

Natera Accounts Payable Historical Data

* Premium members only.

The historical data trend for Natera's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera Accounts Payable Chart

Natera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.08 29.40 13.75 33.35 28.32

Natera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.97 39.62 28.32 53.97 65.23
HAM:45E
59GF Score
Natera Inc HAM:45E
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natera Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €65 Mil mean?
Natera (HAM:45E) has a Accounts Payable of €65 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Natera and its competitors.
Is Natera's Accounts Payable too high?
Natera's current Accounts Payable is €65 Mil. Overall, Natera has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Accounts Payable compare to ?
Natera's Accounts Payable of €65 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Diagnostics & Research company?
A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Natera and its competitors. Natera's current Accounts Payable is €65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (HAM:45E) is currently considered Significantly Overvalued. The stock's GF Value™ is €185.01, compared to a current price of €274.40 — trading 48.3% above its estimated fair value. The current Accounts Payable is €65 Mil. Natera's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Natera (HAM:45E), the current Accounts Payable is €65 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natera (HAM:45E) Overvalued in 2026?

Based on GuruFocus' analysis, Natera stock appears to be overvalued. The current stock price of €274.40 is trading 48.3% above its estimated GF Value™ of €185.01. GuruFocus considers Natera to be Significantly Overvalued.

Key valuation signals for HAM:45E:

  • Accounts Payable: €65 Mil
  • GF Value™: €185.01 vs. price of €274.40 (48.3% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the HAM:45E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natera Business Description

Comparable Companies
Other Exchanges NTRA:USANTRA:Mexico
Address 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
59GF Score

Get the complete analysis for HAM:45E

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€274.40
Price
€185.01
GF Value